Open AccessImpact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study
Author(s) -
Thomas A. Rasmussen,
Lakshmi Rajdev,
Ajantha Rhodes,
Ashanti Dantanarayana,
Surekha Tennakoon,
Socheata Chea,
Tim Spelman,
Shelly Lensing,
Rachel L. Rutishauser,
Sonia Bakkour,
Michael P. Busch,
Janet D. Siliciano,
Robert F. Siliciano,
Mark H. Einstein,
Dirk P. Dittmer,
Elizabeth Chiao,
Steven G. Deeks,
Christine M. Durand,
Sharon R Lewin
Publication year - 2021
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1530
Subject(s) - medicine , nivolumab , ipilimumab , immunology , oncology , viral load , cancer , immune checkpoint , virology , immunotherapy , virus
Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer.